Nimbus Therapeutics Completes Dose Escalation for Novel WRN Inhibitor NDI-219216 in MSI-H Tumors
核心洞察
Nimbus Therapeutics (搜索) completed dose escalation for NDI-219216 (搜索), a novel WRN (搜索) inhibitor targeting MSI-H tumors (搜索), nine months ahead of schedule with favorable safety profile.
The Phase 1/2 trial showed no dose-limiting toxicities or severe treatment-related adverse events through maximum administered dose, with robust target engagement lasting over 24 hours.
NDI-219216 (搜索) demonstrated early clinical activity in patients with MSI-H tumors (搜索), addressing a significant unmet medical need for patients with limited treatment options.
Nimbus Therapeutics (搜索) announced the successful completion of dose escalation in its Phase 1/2 clinical trial of NDI-219216 (搜索), an investigational non-covalent Werner syndrome helicase (搜索) (WRN (搜索)) inhibitor for treating microsatellite instability-high (MSI-H) tumors. The biotechnology company completed this critical milestone approximately nine months ahead of schedule, driven by accelerated patient enrollment across global clinical sites.
Favorable Safety Profile and Target Engagement
The dose escalation portion of the trial demonstrated that NDI-219216 (搜索) maintains a favorable safety profile, with no dose-limiting toxicities or severe treatment-related adverse events observed through the maximum administered dose. Notably, no maximum tolerated dose was reached during the escalation phase. Pharmacokinetic and pharmacodynamic data revealed that NDI-219216 achieved robust WRN (搜索) target engagement for more than 24 hours at multiple dose levels.
"Completing dose escalation represents an important milestone in the clinical development of NDI-219216 (搜索)," said Anita Scheuber, M.D., Ph.D., Senior Vice President, Therapeutic Area Head, Oncology at Nimbus. "We are encouraged by the favorable safety profile and robust target coverage that is translating into early clinical activity in patients."
Clinical Trial Design and Next Steps
The Phase 1/2 clinical trial (NCT06898450) is an open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of NDI-219216 (搜索) in patients with advanced solid tumors (搜索). The study is structured in three parts: Part A (dose escalation), Part B (dose optimization), and Part C (dose expansion). With Part A now complete, the trial is advancing to Part B, which will determine the recommended dose for further evaluation.
Addressing Unmet Medical Need
The accelerated timeline reflects the significant unmet need in the MSI-H tumor patient population. "The accelerated timeline, driven by strong patient recruitment, underscores the significant unmet need in this patient population," Scheuber noted. "These results reinforce our confidence in NDI-219216 (搜索)'s differentiated profile and its potential to address patients with MSI-H tumors (搜索) who have limited treatment options."
Mechanism of Action and Preclinical Evidence
NDI-219216 (搜索) is a highly potent and selective non-covalent investigational inhibitor of Werner syndrome helicase (搜索) activity. WRN (搜索) is a DNA helicase required for DNA replication and DNA repair and represents a validated synthetic lethal target for tumors with microsatellite instability. MSI is a phenotypic consequence of deficient mismatch repair and occurs in various tumor types, including colorectal, gastric, and endometrial cancers.
In preclinical studies, treatment with NDI-219216 (搜索) exhibited robust antitumor activity across multiple cell line-derived xenograft and patient-derived xenograft MSI-H tumor models, including models for colorectal, gastric, and endometrial cancers. The company plans to share clinical data at an upcoming scientific conference.